Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $18.75.

Several equities analysts have recently commented on the stock. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. JPMorgan Chase & Co. reduced their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Finally, Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 10th.

Insider Buying and Selling

In related news, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This represents a 21.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 62,204 shares of company stock worth $280,089. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its stake in shares of Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock valued at $175,000 after purchasing an additional 39,627 shares in the last quarter. Millennium Management LLC raised its stake in Lexeo Therapeutics by 654.8% in the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after buying an additional 929,538 shares in the last quarter. Acadian Asset Management LLC bought a new position in Lexeo Therapeutics in the first quarter worth approximately $85,000. Rhumbline Advisers lifted its holdings in Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after buying an additional 4,995 shares during the period. Finally, Cerity Partners LLC bought a new stake in Lexeo Therapeutics during the 2nd quarter valued at $50,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock opened at $4.74 on Thursday. Lexeo Therapeutics has a 1-year low of $3.60 and a 1-year high of $10.99. The company’s fifty day simple moving average is $4.89 and its 200-day simple moving average is $6.25. The stock has a market capitalization of $372.18 million, a PE ratio of -3.27 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, research analysts anticipate that Lexeo Therapeutics will post -1.21 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.